Company profile for Lexeo Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

LEXEO Therapeutics is a New York City based clinical stage gene therapy biotechnology company with a focus on hereditary and acquired diseases of high unmet need. Founded in 2018 based on 25 years of research at a leading scientific institution, LEXEO's investigational therapies have the potential to offer gene therapy based treatments to address many diseases that have eluded today's existing drug delivery platforms. Our mis...
LEXEO Therapeutics is a New York City based clinical stage gene therapy biotechnology company with a focus on hereditary and acquired diseases of high unmet need. Founded in 2018 based on 25 years of research at a leading scientific institution, LEXEO's investigational therapies have the potential to offer gene therapy based treatments to address many diseases that have eluded today's existing drug delivery platforms. Our mission at LEXEO is to lead the field of gene therapy as a fully integrated biotechnology company; discovering, developing and delivering treatments and cures to some of today's most devastating diseases

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
430 East 29th Street, 14th Floor, New York, NY 10016
Telephone
Telephone
(212) 547-9879
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/05/3181363/0/en/Lexeo-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Operational-Highlights.html

GLOBENEWSWIRE
05 Nov 2025

https://www.globenewswire.com/news-release/2025/10/20/3169762/0/en/Lexeo-Therapeutics-Announces-Closing-of-Public-Offering-and-Concurrent-Private-Placement-and-Exercise-in-Full-of-the-Underwriters-Option-to-Purchase-Additional-Shares-in-the-Public.html

GLOBENEWSWIRE
20 Oct 2025

https://www.globenewswire.com/news-release/2025/10/16/3168360/0/en/Lexeo-Therapeutics-Announces-Proposed-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html

GLOBENEWSWIRE
16 Oct 2025

https://www.globenewswire.com/news-release/2025/10/07/3162307/0/en/Lexeo-Therapeutics-Announces-Progress-in-FDA-Discussions-for-Accelerated-Approval-Pathway-and-Positive-Interim-Clinical-Data-for-LX2006-in-Friedreich-Ataxia-Cardiomyopathy.html

GLOBENEWSWIRE
07 Oct 2025

https://www.globenewswire.com/news-release/2025/08/14/3133352/0/en/Lexeo-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Operational-Highlights.html

GLOBENEWSWIRE
14 Aug 2025

https://www.globenewswire.com/news-release/2025/07/07/3110900/0/en/Lexeo-Therapeutics-Announces-FDA-Breakthrough-Therapy-Designation-for-LX2006-in-Friedreich-Ataxia.html

GLOBENEWSWIRE
07 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty